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INTRODUCTION 
The average incidence of acute Myocardial Infarction 
(MI) is around 208 per 100,000 person years.
1
 Ischemic 
heart disease, previously considered a disease of the 
developed nations, is now affecting less developed 
nations too, with a large share of the global cases of 
ischemic heart disease being in developing countries.
2
 MI 
carries high mortality and morbidity, and early 
reperfusion is the one measure that consistently improves 
outcomes.
1
  
Early reperfusion is best accomplished by Primary 
Percutaneous Intervention (PPCI). However, in many 
regions of the world, patients present to centers that are 
not equipped for primary PCI.
3
 
The one-year mortality rate of both PPCI and 
thrombolysis are similar and time delay to perfusion 
seems crucial to determining the outcomes. ACCF/AHA 
guidelines recommend that fibrinolytic therapy be 
instituted if the patient is being treated at a non-PCI 
capable hospital. In India where the majority of the 
population is rural, and access to PCI capable hospital is 
limited, early thrombolysis is a valid option for 
reperfusion. Thrombolysis in the setting of a developing 
country has some advantages namely: easily available, 
less expensive, easier to administer, therefore less 
expertise required.
4
 
Thrombolysis with intravenous streptokinase has a 
success rate of 44%. The ECG is a low cost non-invasive 
method to detect the success or failure of thrombolysis, 
and the success of thrombolysis (achievement of TIMI 3 
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flow) is indicated by resolution of ST segment elevation. 
Certain factors are associated with failure of 
thrombolysis. These include longer door to needle time, 
high total count, diabetes, hypertension and anterior 
myocardial infarction.
5
 Patients with factors that are 
associated with a failure of thrombolysis would have 
better outcomes with primary PCI. 
Failure of thrombolysis with streptokinase and factors 
associated with reperfusion failure has not been studied in 
our population. Our study aimed to determine, by using 
ECG criteria, the failure rate of thrombolysis with 
streptokinase in acute myocardial infarction in patients 
presenting to our hospital on the west coast of South 
India. We also aimed to find factors associated with 
failure of thrombolysis in the population under study. 
METHODS 
The study was a prospective observational study 
conducted in a medical college hospital in Mangalore, 
South India. Patients with acute myocardial infarction as 
diagnosed by clinical features and ST elevation of at least 
2 mm in 2 leads in ECG who were thrombolysed with 
streptokinase were included in the study. Patients who 
had contraindications to thrombolysis, who presented to 
hospital more than 12 hours after symptom onset, who 
had bundle branch block and those who had been 
previously thrombolysed with streptokinase were 
excluded. 
A brief history and directed physical examination were 
done.  
An ECG was recorded prior to starting streptokinase 
infusion. The maximum height of ST elevation in the lead 
that was worst affected was measured with a plastic ruler.  
1.5 million Units of streptokinase were infused over 1 
hour. A second ECG was recorded 90 minutes after the 
first. The ST elevation in the worst affected lead was 
measured once more and the reduction in height noted. If 
the reduction in the ST elevation was less than 50% then 
the thrombolysis was considered a failure.  
The Statistical Package for Social Sciences version 13 
(SPSS Inc., Chicago, IL, USA) was used for analysis of 
the data in our study. Mean and standard deviation was 
used to express the numerical data while frequency and 
percentages were used to record the categorical data. P 
<0.05 was considered as significant, chi-square test was 
used to compare the association of variables for 
categorical data and for numerical data, t-test was used.  
RESULTS 
This study was conducted in the city of Mangalore, a city 
on the west coast of South India. A total of 100 patients 
admitted with AMI who were thrombolysed with 
streptokinase were recruited of which 26 were female and 
74 were male. 63 patients had failed thrombolysis with 
streptokinase compared to 37 patients who had a 
successful thrombolysis (Fisher’s exact test P = 0.036) 
Patients with Anterior Wall MI (AWMI) had the highest 
rate of failure of thrombolysis (43, 68.3%) followed by 
Inferior Wall Myocardial Infarction (IWMI) (14, 22.2%). 
The mean symptom needle time in patients with failed 
and successful thrombolysis was 7.95 hours and 3.03 
hours respectively (t test 11.95 P <0.001). 35 (55.6%) 
patients among the failed group had DM (OR 2.6, CI 1.1-
6) (x
2 
= 5.003 P = 0.025). 61% of our study population 
were smokers and among these 69.8% failed 
thrombolysis with streptokinase.  
Our study showed that patients who failed reperfusion 
had a higher admission heart rate (102.51 beats/min) and 
diastolic blood pressure. The mean systolic BP in the 
failure group was 150 mmHg and in the successful group 
was at 127 mmHg.   
 
Table 1: Results of different parameters. 
    Mean ± SD 
Mann 
Whitney 
Z value 
P T value 
Trop T 
F 0.1551 ± 0.26183 
0.044 0.965 
  
  S 0.1578 ± 0.35991 
Platelets 
F 295904.76 ± 367398.9 
1.717 0.089 
  
  S 190867.57 ± 71680.689 
TC 
F 12061.9 ± 4718.407 
0.69 0.945 
  
  S 12178.38 ± 11961.051 
DM years 
F 7.54 ± 4.061 
0.031 0.975 
  
  S 7.58 ± 3.423 
Pack years 
F 32.95 ± 16.4 
1.426 0.159 
  
  S 26.47 ± 14.552 
FBS 
F 181.88 ± 80.596 
  0 6.125 
S 96.97 ± 17.099 
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Hb 
F 13 ± 2.098   
  
0 
  
3.974 
S 14.55 ± 1.433 
Na 
F 135.59 ± 3.191   
  
0.008 2.711 
S 133.95 ± 2.391 
K 
F 3.97 ± 0.5088   
  
0.618 0.5 
S 3.919 ± 0.4618 
Cl 
F 102.24 ± 5.018   
  
0.073 1.811 
S 100.59 ± 2.976 
HR 
F 102.51 ± 16.196   
  
0 6.608 
S 82.7 ± 10.885 
Systolic BP 
F 150.29 ± 20.484   
  
0 6.222 
S 127.3 ± 11.983 
Diastolic BP 
F 91.58 ± 10.403   
  
  
0 6.22 S 78.59 ± 9.415 
S 3.03 ± 1.258 
Creatinine 
F 1.157 ± 0.3876   
  
0.294 1.054 
S 1.084 ± 0.2205 
HTN years 
F 10 ± 4.634   
  
0.308 1.03 
S 8.5 ± 5.721 
PACK years 
F 32.95 ± 16.4   
  
0.159 1.426 
S 26.47 ± 14.552 
Cholesterol 
F 215.54 ± 67.358   
  
0.182 1.343 
S 234.43 ± 68.859 
LDL 
F 140.21 ± 39.299   
  
0.002 3.181 
S 169.86 ± 53.458 
Age 
F 58.38 ± 11.296   
  
0.275 1.098 
S 55.97 ± 9.251 
Low HDL 
43 28 ± 71 
0.624 0.43 NS 
68.30% 75.70% ± 71% 
Normal LDL 
20 9 ± 29   
  
  
  
  
  31.7% 24.3% ± 29.0% 
31-40 years 
4 0 ± 4   
  
0.036 SIG 
6.3% 0.0% ± 4.0% 
41-50 
11 13 ± 24   
  
  
  
  
  17.50% 35.10% ± 24% 
51-60 
22 17 ± 39   
  
  
  
  
  34.90% 45.90% ± 39% 
61-80 
24 7 ± 31   
  
  
  
  
  38.10% 18.90% ± 31% 
Above 80 
2 0 ± 2   
  
  
  
  
  3.20% 0% ± 2% 
High LDL 
39 28 ± 67 
1.999 0.157 NS 
61.90% 75.70% ± 67% 
Normal LDL 
24 9 ± 33   
  
  
  
  
  38.1% 24.3% ± 33.0% 
High TGL 
39 18 ± 57 
1.671 0.196 NS 
61.90% 48.60% ± 57% 
Normal TGL 
24 19 ± 43   
  
  
  
  
  38.10% 51.45% ± 43% 
High cholesterol 
38 26 ± 64 
1.002 0.317 NS 
60.30% 70.30% ± 64% 
Normal cholesterol 
25 11 ± 36   
  
  
  
  
  39.7% 29.7% ± 36.0% 
Non smokers 
19 20 ± 39   
  
0.01 SIG 
30.20% 54.10% ± 39% 
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Heavy smokers 
32 8 ± 40   
  
  
  
  
  50.80% 21.60% ± 40% 
Moderate smokers 
10 9 ± 19   
  
  
  
  
  15.90% 24.30% ± 19% 
Occasional smokers 
2 0 ± 2   
  
  
  
  
  
  
  
  
3.20% 0% ± 2% 
66.70% 75.70% ± 70% 
DM 
N 
28 25 ± 53 
5.003 0.025 SIG 
44.4% 67.6% ± 53.0% 
Y 
35 12 ± 47   
  
  
  
  
  55.60% 32.40% ± 47% 
HTN 
N 
29 19 ± 48 
0.264 0.607 
  
  46.0% 51.4% ± 48.0% 
Y 
34 18 ± 52   
  
  
  
  
  54.0% 48.6% ± 52.0% 
High creatinine 
19 19 ± 38 
6.131 0.047 SIG 
30.20% 51.40% ± 38% 
Normal creatinine 
32 16 ± 48   
  
  
  
  
  
  
  
  
50.80% 43.20% ± 48% 
19% 5.40% ± 14% 
Anterior infarct 
43 7.00% ± 50   
  
0 HS 
68.30% 18.90% ± 50% 
Inferior infarct 
14 8 ± 22   
  
  
  
  
  22.20% 21.60% ± 22% 
Lateral infarct 
4 17 ± 21   
  
  
  
  
  6.30% 45.90% ± 21% 
Antero septal infarct 
2 5 ± 7   
  
  
  
  
  3.20% 13.50% ± 7% 
Normal ESR 
39 34 ± 73 
10.635 0.001 HS 
61.90% 91.90% ± 73% 
High ESR 
24 3 ± 27   
  
  
  
  
  38.10% 8.10% ± 27% 
 
DISCUSSION 
The findings from CAPTIM and Prague 2 conclude that a 
PPCI is the best reperfusion strategy for AMI if done 
within 1 hour. Between 1 and 3 hours, thrombolysis is 
effective and beyond three hours, thrombolysis is less 
effective and the patient should be transferred to a center 
for PPCI. However, in developing countries, not all 
patients present to a center that is equipped for PCI. In 
such cases early thrombolysis confers a survival benefit.
6
 
In developed nations, reperfusion strategies include PCI 
and thrombolysis with tissue plasminogen activator (t-
PA). The GUSTO trial did not find any significant 
difference between the 30 day mortality in patients 
thrombolysed with t-PA and streptokinase.
7
 However at 
the end of the first year of follow up, mortality rates were 
significantly lower with t-PA than with streptokinase.
8
 In 
spite of this, it must be taken in to account that t-PA costs 
ten times as much as streptokinase and health care in 
developing countries like India is paid for by the 
individual, as health insurance systems are not 
completely in place yet. Therefore, streptokinase 
continues to be a viable treatment option in developing 
countries to achieve reperfusion in patients admitted with 
acute MI.
9
 
Coronary artery disease in India has a prevalence of 
64.37 per 1000 people and is anticipated to affect 65 
million Indians by the year 2015. Patients in India 
admitted with an ACS have a higher rate of STEMI than 
those in developed nations.
10
 
The problems regarding care of acute myocardial 
infarction in India are, firstly that a well-equipped trained 
Emergency Medical Service (EMS) to administer pre 
hospital thrombolysis is not yet in place, and secondly 
health insurance is not universal, and patients often pay 
out of pocket for medical care. This means that in a 
country that has the lowest per capita income among the 
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G 20 nations; cost of therapy becomes a major 
consideration. Coronary vascular disease is no longer a 
disease of the wealthy and in caring for the poor who 
present with myocardial infarction, often to a centre that 
is not PCI capable, the financially more appropriate 
thrombolytic agent streptokinase is often used.  
Our study aimed at quantifying the failure rate of 
thrombolysis with streptokinase in acute myocardial 
infarction and finding patient and logistic factors 
associated with failure. Failure of thrombolysis was 
defined as less than TIMI 3 flow after thrombolysis. We 
used ECG criteria as a bedside non-invasive test to 
determine success/failure of thrombolysis. Sutton et al 
defined ECG criteria for failure of thrombolysis as less 
than 50% resolution of ST segment elevation in the most 
affected lead and absence of idioventricular rhythm.
11
 
Our study demonstrated a 63% failure rate of 
thrombolysis with streptokinase. Higher failure rates 
were seen in diabetics, patients with anterior infarct, and 
with a longer symptom to needle time. A highly 
significant correlation was found between failed 
thrombolysis and high admission blood pressure, 
tachycardia, and high serum sodium. 
The higher failure rate in our study - 63% vs. 54% in 
GUSTO 1 trial is perhaps due to the much higher 
symptom needle time. The catchment area of the study 
centre is the surrounding villages and small towns. The 
area is mountainous and rapid travel is difficult. 
Therefore significantly longer time is taken to reach 
hospital from the time of symptom onset. The effect of 
the location of the occluded artery on thrombolysis 
varies. In our study, patients with anterolateral MI had 
the highest failure rates, similar to previous studies, 
including the INJECT trial.
12
 However in the GUSTO 1 
study, patients with occlusion of the right and left 
circumflex arteries had worse outcomes than those with 
occlusion of the Left Anterior Descending artery (LAD).
7 
The influence of the occluded artery on the outcome of 
thrombolysis is influenced by the thrombus burden, 
plaque burden and also the development of collaterals.  
Previous studies show that the single factor with greatest 
effect on the success of reperfusion after an infarction is 
the timeliness of reperfusion. Myocardial necrosis is a 
process that increases with the elapse of time, with the 
muscle fibre passing through the stages of dysfunction, 
stunning and finally death.
13
 This was corroborated in our 
study in which the mean Symptom Needle (S/N) time in 
the successful group was 3.03 hours as opposed to 7.95 
hours in the group, which failed reperfusion. Even in the 
developed world, the time to admission and the time to 
treatment in patients admitted with MI is still prolonged, 
and resources must be allocated to improve these times.
14
 
10 to 25% of patients admitted with MI have diabetes 
mellitus. In our study the figure was 47%, which is 
unsurprising, as India has a high prevalence of diabetes 
mellitus. Our study demonstrated a poor thrombolytic 
outcome in patients with diabetes, with 55.6% of those 
who failed thrombolysis being diabetics. The increased 
failure rates in diabetics are due to decreased myocardial 
sensation, leading to increased symptom needle time.  
Admission blood glucose level after AMI is
 
an 
independent predictor of long-term mortality in patients, 
even in patients without diabetes, and among patients 
who are not known diabetics, admission glucose levels of 
200 mg/dL or more
 
after MI have mortality rates 
comparable to those of established diabetics.
15 
Admission glucose was found to be a better predictor of 
long-term outcome than HbA1c.
16
 
In our study there was no difference between the S/N 
times in diabetics and non-diabetics unlike in previous 
published reports. This may be due to the general 
tendency to an increased S/N time in most of our patients. 
In our study hypertension and higher admission blood 
pressure showed a correlation with reperfusion failure. 
Other studies also show that hypertensives have a higher 
rate of stroke and sudden cardiac death.
17 
This may be 
related to factors such as left ventricular hypertrophy and 
endothelial damage.
18
 This might indicate a greater need 
to normalize blood pressure before starting thrombolytic 
therapy or switching to alternate means of therapy if the 
pressure remains high. In our study, tachycardia at 
admission was associated with a higher rate of 
reperfusion failure. This has been demonstrated in other 
studies as well, and is perhaps due to the fact that 
tachycardia increases oxygen demand and cardiac work.
19
 
This effect of the heart rate on outcome is further 
worsened by diabetes mellitus.
20
 
Our study showed that the rate of reperfusion failure 
increased with advancing age. In addition, elderly 
patients who are admitted with MI have higher rate of 
stroke, cardiogenic shock, bleeding and reinfarction.  
Many of the elderly who are admitted with acute MI have 
contraindications to thrombolysis. Therefore, 
thrombolysis in the elderly is less effective and safe than 
in the young.  
We found that smokers, especially heavy smokers, had a 
higher rate of failure of reperfusion. However, previous 
studies show no difference in mortality between smokers 
and non-smokers, and one retrospective study shows that 
smokers admitted with acute MI have better outcomes 
than non-smokers.
21
 This phenomenon, where smokers 
admitted to hospital with myocardial infarction have a 
better outcome is known as the smokers’ paradox. 
However, this is perhaps because smokers present at a 
younger age, and have a lower incidence of diabetes and 
hypertension, and the early presentation and the absence 
of comorbidities are perhaps responsible for this 
observation.
22
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Limitations of the study  
This was a purely observational study on patients who 
presented to hospital with acute MI, and who refused the 
option of PPCI. It excluded patients who could afford 
PPCI, and those who were thrombolysed with more 
expensive tenecteplase, which is superior to 
streptokinase. Since the aim of the study was to find the 
rate of failure of thrombolysis, as determined by ECG 
criteria, with streptokinase and factors associated with 
failure, the patients were not followed up for study 
purpose after thrombolysis. Some of the patients 
underwent rescue angioplasty; however these details were 
not collected or analyzed.  
CONCLUSION 
In many developing countries, including India, PCI is not 
as easily accessible as it is in the developed world, and 
thrombolysis is a financially more affordable alternative, 
which is often used. However, in acute myocardial 
infarction, thrombolysis with streptokinase had a high 
rate of failure of reperfusion, and factors associated with 
failure were increased symptom needle time, diabetes, 
increased Admission blood pressure, smoking, and in the 
elderly. Therefore in spite of the increased cost, these are 
patients who would benefit from referral for primary 
percutaneous intervention. 
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